Association of high‐dose radioactive iodine therapy with PPM1D ‐mutated clonal hematopoiesis in older individuals
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Jaeryuk Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Clonal Hematopoiesis, Mutation, Thyroid Neoplasms. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, Republic of Korea, Seoul National University, Ministry of Health and Welfare, Republic of Korea.
Abstract (Originalsprache)
While radioactive iodine therapy (RAIT) has been an effective treatment for thyroid cancer, its link to clonal hematopoiesis (CH) has been yet underexplored. In this study, error‐corrected sequencing (median depth: 1926×) of 93 CH‐related genes was performed from the blood samples of 358 thyroid cancer patients, including 110 controls (no RAIT) and 248 RAIT recipients. RAIT recipients were stratified into low‐ and high‐dose groups using a 7.4 GBq cutoff. Multivariable logistic regression revealed that the high‐dose group had a higher CH prevalence with variant allele frequency (VAF) higher than 2% compared to controls, especially in patients aged ≥50 (OR = 2.44, CI = 1.04–6.00, P = 0.04). Thirteen genes had mutations with VAF >2%, with DNMT3A , TET2 , and PPM1D being the most common. Notably, only the PPM1D mutations were significantly linked to RAIT, occurring more frequently in the high‐dose group (13%) compared to the low‐dose group (5%) or controls (2%) at a VAF cutoff of 0.5%. In silico analyses indicated that truncating PPM1D mutations confer a selective advantage under high‐dose RAIT and with older age. Although the prognostic implications of PPM1D ‐mutated CH remain to be further elucidated, these findings offer valuable insights for optimizing RAIT dosing in thyroid cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea.
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.
- Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea.
- Department of Biochemistry and Molecular Biology, Kangwon National University School of Medicine, Gangwon, Korea.
ORCID-Profile: Jaeryuk Kim, Jin Chul Paeng, Young Joo Park, Jong-Il Kim
Förderung
- Ministry of Science and ICT, Republic of Korea
- Seoul National University
- Ministry of Health and Welfare, Republic of Korea
- Ministry of Education, Republic of Korea
Zitieren
APA
Kim, J., Bae, S., Choi, J., Im, S. W., Cha, B., Jung, G., Cho, S. W., Seo, E. J., Lee, Y. A., Paeng, J. C., Park, Y. J., & Kim, J. I. (2025). Association of high‐dose radioactive iodine therapy with PPM1D ‐mutated clonal hematopoiesis in older individuals. Molecular Oncology. https://doi.org/10.1002/1878-0261.70078
Vancouver
Kim J, Bae S, Choi J, Im SW, Cha B, Jung G, et al. Association of high‐dose radioactive iodine therapy with PPM1D ‐mutated clonal hematopoiesis in older individuals. Molecular Oncology. 2025. doi:10.1002/1878-0261.70078
BibTeX
@article{Kim2025,
author = {Kim, Jaeryuk and Bae, Sungwoo and Choi, Jaeyong and Im, Sun-Wha and Cha, Bukyoung and Jung, Gyeongseo and Cho, Sun Wook and Seo, Eul-Ju and Lee, Young Ah and Paeng, Jin Chul and Park, Young Joo and Kim, Jong-Il},
title = {Association of high‐dose radioactive iodine therapy with PPM1D ‐mutated clonal hematopoiesis in older individuals},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70078}
}
EUVIMED